Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

NCT02670616 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: vincristine
DRUG: Prednisolone

Sponsor

Samsung Medical Center